Dapagliflozin and Cardiac Reverse Remodeling: New Insights in the Mechanistic Puzzle of SGLT2 Inhibitors.
作者信息
Chatur Safia, Churchill Timothy W
机构信息
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Boston, Massachusetts.
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Boston, Massachusetts; Cardiovascular Performance Program, Massachusetts General Hospital, Boston, Massachusetts.
出版信息
J Am Soc Echocardiogr. 2025 May;38(5):404-408. doi: 10.1016/j.echo.2025.01.002. Epub 2025 Jan 6.
Abstract
摘要
相似文献
1
Dapagliflozin and Cardiac Reverse Remodeling: New Insights in the Mechanistic Puzzle of SGLT2 Inhibitors.达格列净与心脏逆向重构：SGLT2抑制剂机制谜题的新见解
J Am Soc Echocardiogr. 2025 May;38(5):404-408. doi: 10.1016/j.echo.2025.01.002. Epub 2025 Jan 6.
2
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.达格列净是一种选择性钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，通过梗死大鼠心脏中的信号转导和转录激活因子3（STAT3）信号通路调节巨噬细胞极化，从而减轻心脏纤维化。
Free Radic Biol Med. 2017 Mar;104:298-310. doi: 10.1016/j.freeradbiomed.2017.01.035. Epub 2017 Jan 26.
3
Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus.SGLT2抑制对链脲佐菌素诱导的糖尿病大鼠心脏重塑的影响，1型糖尿病模型
Antioxidants (Basel). 2022 May 17;11(5):982. doi: 10.3390/antiox11050982.
4
Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.使用半机制模型分析钠-葡萄糖协同转运蛋白2抑制剂的疗效。
Front Pharmacol. 2014 Oct 13;5:218. doi: 10.3389/fphar.2014.00218. eCollection 2014.
5
Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2.达格列净通过抑制巨噬细胞介导体液炎症来预防小鼠慢性心力衰竭，与 SGLT2 无关。
Cell Rep Med. 2023 Dec 19;4(12):101334. doi: 10.1016/j.xcrm.2023.101334.
6
Peripartum dapagliflozin improves late-life maternal cardiovascular outcomes in a murine model of superimposed preeclampsia.围产期使用达格列净可改善先兆子痫叠加小鼠模型中母体晚年的心血管结局。
Am J Obstet Gynecol. 2025 Mar 29. doi: 10.1016/j.ajog.2025.03.035.
7
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.新型钠-葡萄糖协同转运蛋白2抑制剂DWP16001与达格列净和依帕列净的比较药代动力学和药效学
Pharmaceutics. 2020 Mar 15;12(3):268. doi: 10.3390/pharmaceutics12030268.
8
Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂达格列净的急性抗心律失常作用降低了心房肌细胞的兴奋性。
Basic Res Cardiol. 2024 Feb;119(1):93-112. doi: 10.1007/s00395-023-01022-0. Epub 2024 Jan 3.
9
Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.达格列净不能预防阿霉素诱导的小鼠肾损伤。
Kidney Blood Press Res. 2024;49(1):81-90. doi: 10.1159/000536088. Epub 2024 Jan 5.
10
Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?达格列净对心力衰竭患者运动、心脏重塑、生物标志物以及肾脏和肺功能的影响：不如预期？
Front Cardiovasc Med. 2025 Mar 17;12:1542870. doi: 10.3389/fcvm.2025.1542870. eCollection 2025.
引用本文的文献
1
Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.心力衰竭与宽QRS波：临床与药理学视角
Biomedicines. 2025 Jun 13;13(6):1462. doi: 10.3390/biomedicines13061462.
本文引用的文献
1
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI).恩格列净预防心肌梗死后左心室容积和收缩功能恶化（EMPRESS-MI研究）
Eur J Heart Fail. 2025 Mar;27(3):566-576. doi: 10.1002/ejhf.3560. Epub 2024 Dec 15.
2
Harnessing SGLT2 Inhibitors: A New Frontier in Cardiac Remodeling for Nondiabetic Heart Failure.利用钠-葡萄糖协同转运蛋白2抑制剂：非糖尿病性心力衰竭心脏重塑的新前沿
JACC Cardiovasc Imaging. 2024 Dec;17(12):1409-1410. doi: 10.1016/j.jcmg.2024.09.007.
3
Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction.达格列净对射血分数降低的心力衰竭患者左心室重构及充盈压的影响。
J Am Soc Echocardiogr. 2025 May;38(5):395-403. doi: 10.1016/j.echo.2024.10.009. Epub 2024 Oct 28.
4
Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome.达格列净对心力衰竭患者心脏形变及继发临床结局的影响。
JACC Cardiovasc Imaging. 2024 Dec;17(12):1399-1408. doi: 10.1016/j.jcmg.2024.05.014. Epub 2024 Jul 17.
5
Left Atrioventricular Coupling Index: A Novel Diastolic Parameter to Refine Prognosis in Heart Failure.左房室耦联指数：一种用于改善心力衰竭预后的新型舒张参数。
J Am Soc Echocardiogr. 2024 Nov;37(11):1038-1046. doi: 10.1016/j.echo.2024.06.013. Epub 2024 Jun 29.
6
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.恩格列净的疗效和安全性根据射血分数降低的心力衰竭（HFrEF）患者的背景利尿剂使用情况： EMPEROR-Reduced 的事后分析。
JACC Heart Fail. 2024 Jan;12(1):35-46. doi: 10.1016/j.jchf.2023.06.036. Epub 2023 Sep 13.
7
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.恩格列净和利尿剂在射血分数保留的心力衰竭患者中的安全性和疗效：来自 EMPEROR-Preserved 试验的事后分析。
JAMA Cardiol. 2023 Jul 1;8(7):640-649. doi: 10.1001/jamacardio.2023.1090.
8
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.达格列净与利尿剂在射血分数轻度降低或保留的心衰中的应用：DELIVER 试验。
Eur Heart J. 2023 Aug 14;44(31):2930-2943. doi: 10.1093/eurheartj/ehad283.
9
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study.达格列净对慢性心力衰竭患者心脏重构的影响：DAPA-MODA 研究。
Eur J Heart Fail. 2023 Aug;25(8):1352-1360. doi: 10.1002/ejhf.2884. Epub 2023 Jun 7.
10
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial.达格列净对慢性肾脏病患者超声心动图心脏结构和功能指标的影响：DECODE-CKD 试验。
Kidney360. 2023 Feb 1;4(2):143-149. doi: 10.34067/KID.0006982022. Epub 2022 Dec 18.
Zotero 插件